Navigation Links
Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
Date:10/24/2010

BEIJING, Oct. 24 /PRNewswire-Asia-FirstCall/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

As part of the bidding process, the Beijing CDC evaluated potential suppliers and assigned scores for different factors, including product quality, service and price. Based on the comprehensive score, Sinovac was selected as the first priority supplier. Based on the first contract with the Beijing CDC, Sinovac will supply 375,000 doses of its seasonal influenza vaccine, Anflu®, valued at RMB 8.8 million or approximately $1.3 million. The total quantity to be supplied will depend on the actual demand in Beijing.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "Being selected as the first priority supplier of seasonal influenza vaccine by the Beijing CDC is further validation of Sinovac's leading quality assurance system. We look forward to working closely with the Beijing CDC to deliver our Anflu vaccine to the citizens under the vaccination campaign."

In order to prevent and control the seasonal flu, the Beijing CDC plans to provide free inoculations against the seasonal influenza to Beijing citizens, inclusive of elderly people over the age of 60 and elementary and secondary school age children. And Beijing CDC plans to order total 2.8 million doses for this vaccination campaign. Previously, school students were inoculated with the influenza vaccine at a charge of 20 RMB per person with allowances from the Bureau.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For further information, please contact:Helen YangSinovac Biotech Ltd.Tel:  +86-10-8279-9871Fax:  +86-10-6296-6910Email: info@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:   +1-646-536-7025Email: jrando@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Announces Plan to Launch Offering of Common Shares
5. Sinovac Announces Recent Developments
6. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
7. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
9. Sinovac Files Shelf Registration Statement
10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 26, 2016 Story Highlights: ... models within the health care industry is causing providers ... , Deloitte offers a suite of solutions for ... impacting efficient cost optimization: labor resource analysis, revenue cycle ... facilitate better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):